We used an ultrasensitive prostate-specific antigen (PSA) assay with a detection limit of 0.02 g/L for long-term monitoring of PSA changes in 5 patients who were cured by radical prostatectomy and in 10 patients who had failed prostatectomies; 5 patients who underwent cystoprostatectomy were also evaluated with one sample after surgery. Relapse-free periods, determined on the basis of criteria designed specifically for the ultrasensitive assay or proposed for other currently available PSA assays, were calculated for the patients with failed prostatectomies. Tumor-doubling times were also calculated, postsurgery, according to a model that assumes exponential tumor growth over time. We found that prostate cancer relapse, on average, could be diagnosed 420 or 883 days earlier with the ultrasensitive assay than with assays having detection limits of 0.1 or 0.3 g/L, respectively. Tumor-doubling times, calculated after radical prostatectomy, ranged from 67 to 568 days among the 10 patients. We also present evidence that even moresensitive PSA assays might be able to further reduce the relapse-free periods in -50% of the prostate cancer patients who ultimately relapse.
We used an ultrasensitive prostate-specific antigen (PSA) assay with a detection limit of 0.02 g/L for long-term monitoring of PSA changes in 5 patients who were cured by radical prostatectomy and in 10 patients who had failed prostatectomies; 5 patients who underwent cystoprostatectomy were also evaluated with one sample after surgery. Relapse-free periods, determined on the basis of criteria designed specifically for the ultrasensitive assay or proposed for other currently available PSA assays, were calculated for the patients with failed prostatectomies. Tumor-doubling times were also calculated, postsurgery, according to a model that assumes exponential tumor growth over time. We found that prostate cancer relapse, on average, could be diagnosed 420 or 883 days earlier with the ultrasensitive assay than with assays having detection limits of 0.1 or 0.3 g/L, respectively. Tumor-doubling times, calculated after radical prostatectomy, ranged from 67 to 568 days among the 10 patients. We also present evidence that even moresensitive PSA assays might be able to further reduce the relapse-free periods in -50% of the prostate cancer patients who ultimately relapse. Results Figure   1 presents changes in PSA concentrations over time for the five control patients who had been successfully cured by radical prostatectomy (I-V) and for the patients who had failed prostatectomies (1-10). These data were obtained with our ultrasensitive timeresolved immunofluorometric procedure. Table 1 lists  the PSA concentrations for all the control samples and for the cystoprostatectomy patients (evaluated once, long after surgery). According to the criteria we devised for detection of relapse, none of the five control patients fell into the relapse category. Although there was some variation in PSA concentrations with time ( Fig. 1) , no significant consecutive increases of PSA were observed in any of the five control patients.
The relapse-free periods and doubling times for the 10 patients who had failed prostatectomies are presented in Table 2 Table 2 ).
After demonstrating .tgfL, two had PSA >0.020 gfL, and the mean PSA concentration in the cystoprostatectomy group was 0.03 1 g/L. These data suggest that the traces of PSA, circulating in the serum of patients without prostate tissue or evidence of prostate cancer, and which did not change with time, were released by nonprostatic tissue, which is capable of synthesizing PSA, as previously described (25, 26).
Ten patients who had histologically confirmed prostate cancer, and who were treated with radical prostatectomy but ultimately relapsed, were also studied.
PSA changes monitored over long periods in all patients are presented in Fig. 1 27) . A near-linear relationship would then be expected to exist between ln[PSA} and time, and this has been confirmed in our study (Fig. 2) . Using these plots, we calculated tumor-doubling times as described above, and calculated relapse-free periods based on the criteria we established for our ultrasensitive assay and on the criteria previously used with commercially available kits having detection limits of 0.1-0.3 pgfL. These data are presented in Table 2 . In the 10 patients who underwent radical prostatectomy, baseline PSA values were 0.020 LgfL in 7 and >0.020 ,u.gfL in 3, in accordance with previous reports by our group (16, 24) . One patient (patient 3, Fig. 1 ) did not seem to clear his preoperative PSA even after 3 months after the surgery.
However, we could not exclude the possibility that this patient might have tumor cells in his circulation, producing PSA. Such cells could cause a subsequent increase in serum PSA if they were to be successfully implanted.
As determined with our ultrasensitive assay, the relapse-free periods for the 10 patients ( 
